New treatments for HIV-1 in patients with tuberculosis in South Africa
Official title: Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa
Funded at Centre/aids Programme/res/south Africa · NIH-10898925 · Data updated 2026-11-12
This study is looking at how well certain HIV medications work for kids who also have tuberculosis, to make sure they are safe and effective when taken together.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Centre/aids Programme/res/south Africa NIH-funded |
| Lab location | 1 site (Durban, SOUTH AFRICA) |
| Project start | August 3, 2020 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $290,914 |
| NIH project number | 5R01AI152142-05 |
| Project ID | NIH-10898925 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals of all ages, particularly those co-infected with HIV and TB who are undergoing rifampicin-based treatment.
✕Less likely to help
Patients who are not co-infected with HIV and TB or those not receiving rifampicin-based treatment may not benefit from this research.
What this research studies
This research focuses on the effectiveness of second-generation integrase strand transfer inhibitors (InSTIs) like dolutegravir and bictegravir for treating HIV-1 in patients who are also being treated for tuberculosis (TB). Given the high rates of HIV and TB co-infection in South Africa, the study aims to determine the appropriate dosing and safety of these medications, especially in young children who are on rifampicin-based TB treatment. The research will involve assessing how these drugs interact with TB medications and their overall effectiveness in this unique patient population.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with both HIV and TB, enhancing their health outcomes.
How similar studies have gone: Previous research has shown promising results with integrase strand transfer inhibitors in HIV treatment, but this specific approach for co-infected patients is novel.
Where this research is happening
-
Centre/aids Programme/res/south Africa
Durban, South Africa Active
Researchers
- Principal investigator: Naidoo, Anushka — Centre/aids Programme/res/south Africa
- Study coordinator: Naidoo, Anushka
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.